Lawver Teri L has filed 5 insider transactions across 3 companies since March 2024.
Most recent transaction: a grant/award of 100000 shares of Celldex Therapeutics, Inc. ($CLDX) on November 10, 2025.
Activity breakdown: 0 open-market purchases and 1 sale.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov. 10, 2025 | Celldex Therapeutics, Inc. | $CLDX | Lawver Teri L | SVP & Chief Commercial Officer | A | ISO (right to buy) | 100000 | $0.00 | 100,000.0000 | 66,420 | 9999.99% | 100.00% |
| Sept. 25, 2025 | Altimmune, Inc. | $ALT | Lawver Teri L | Director | A | Stock Options (option to buy) | 48800 | $0.00 | 48,800.0000 | 81,477,548 | 9999.99% | 0.06% |
| Feb. 24, 2025 | Altimmune, Inc. | $ALT | Lawver Teri L | Director | A | Stock Options (option to buy) | 69800 | $0.00 | 69,800.0000 | 71,003,399 | 9999.99% | 0.10% |
| March 12, 2024 | DEXCOM INC | $DXCM | Lawver Teri L | EVP Chief Commercial Officer | S | Common Stock | 4764 | $134.41 | 66,641.0000 | 425,500,000 | 6.67% | 0.00% |
| March 8, 2024 | DEXCOM INC | $DXCM | Lawver Teri L | EVP Chief Commercial Officer | A | Common Stock | 26053 | $0.00 | 71,405.0000 | 425,500,000 | 57.45% | 0.01% |